Traws Pharma Inc (TRAW) Stock Analysis

Traws Pharma Inc (TRAW) is a publicly traded company in the HEALTHCARE sector. It trades at $1.42, carries a market capitalization of $22.27M. This page summarizes the public market data, fundamentals, and frequently asked questions for TRAW, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Traws Pharma Inc currently has a Bullish sentiment score of 0.28.

About Traws Pharma Inc

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Newtown, Pennsylvania, focused on developing innovative oncology therapies. The company boasts a promising pipeline of novel treatments aimed at addressing significant unmet medical needs in cancer care. By leveraging advanced research and development capabilities, Traws Pharma is well-positioned to enhance patient outcomes and capitalize on emerging opportunities within the dynamic biopharmaceutical market, mak...

GNG Research Analysis

GNG Research scores Traws Pharma Inc (TRAW) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for TRAW.

Frequently Asked Questions

Does TRAW pay dividends?

Traws Pharma Inc (TRAW) does not currently pay a regular dividend.

What is TRAW's market cap?

Traws Pharma Inc (TRAW) has a market capitalization of $22.27M with a current stock price of $1.42.